TD Waterhouse Canada Inc. Increases Position in Guardant Health, Inc. (NASDAQ:GH)

TD Waterhouse Canada Inc. boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 126.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,929 shares of the company’s stock after buying an additional 1,634 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Guardant Health were worth $89,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in shares of Guardant Health by 243.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,500 shares of the company’s stock worth $351,000 after purchasing an additional 8,147 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Guardant Health by 5.9% in the fourth quarter. MetLife Investment Management LLC now owns 72,149 shares of the company’s stock valued at $2,204,000 after acquiring an additional 4,002 shares in the last quarter. Blue Water Life Science Advisors LP boosted its stake in shares of Guardant Health by 53.9% during the fourth quarter. Blue Water Life Science Advisors LP now owns 694,047 shares of the company’s stock valued at $21,203,000 after acquiring an additional 243,000 shares during the last quarter. Canada Pension Plan Investment Board increased its position in Guardant Health by 77.1% during the 4th quarter. Canada Pension Plan Investment Board now owns 177,500 shares of the company’s stock worth $5,423,000 after purchasing an additional 77,300 shares in the last quarter. Finally, MSH Capital Advisors LLC acquired a new position in Guardant Health in the 4th quarter valued at about $480,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GH has been the topic of several analyst reports. Stephens reaffirmed an “overweight” rating and set a $55.00 price target on shares of Guardant Health in a research note on Wednesday, March 26th. Canaccord Genuity Group lifted their target price on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Mizuho began coverage on Guardant Health in a report on Thursday, April 10th. They issued an “outperform” rating and a $55.00 price target for the company. Scotiabank raised their price objective on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Finally, Barclays dropped their target price on Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Guardant Health has a consensus rating of “Buy” and a consensus price target of $49.00.

Guardant Health Stock Up 1.9 %

Shares of NASDAQ:GH opened at $48.30 on Monday. The company has a market capitalization of $5.96 billion, a price-to-earnings ratio of -13.57 and a beta of 1.45. The company has a 50 day moving average of $43.37 and a two-hundred day moving average of $37.42. Guardant Health, Inc. has a 52-week low of $17.52 and a 52-week high of $50.89.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. On average, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.